Poor
Needs Revision
Patient Risk:
Medium
Summary
Several interaction/safety assertions are either unsupported by the provided label excerpts or overreach beyond what is explicitly stated (e.g., bleeding risk with vitamin E/ginkgo/garlic; liver damage with vitamin A/E; muscle damage with creatine/HMB; CoQ10/vitamin D to mitigate side effects). Grapefruit juice and St. John's Wort claims are not fully supported by the provided label excerpts (grapefruit is supported; St. John's Wort is not).
Category Scores
Accurate Statements
Grapefruit juice can increase Lipitor levels in the blood, especially with excessive consumption (>1.2 liters per day).
Section 7.2 Grapefruit Juice: “Contains one or more components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin, especially with excessive grapefruit juice consumption (>1.2 liters per day).”
Lipitor (atorvastatin) is a statin medication that lowers cholesterol levels in the blood (mechanism: inhibits HMG-CoA reductase).
Section 12.1 Mechanism of Action: “selective, competitive inhibitor of HMG-CoA reductase…”; Section 14.2: “LIPITOR reduces total-C, LDL-C… and increases HDL-C.”
Unsupported Statements
Grapefruit juice can increase Lipitor levels in the blood, leading to increased risk of bleeding or other adverse effects.
The provided label excerpt for grapefruit juice states increased atorvastatin plasma concentrations but does not state bleeding risk or specifically 'bleeding or other adverse effects' attributable to grapefruit juice.
St. John's Wort can decrease the levels of Lipitor in the blood, reducing its effectiveness.
No St. John's Wort interaction is provided in the supplied label excerpts.
Vitamin E can increase the risk of bleeding when taken with Lipitor.
No vitamin E supplement interaction or bleeding-risk statement is provided in the supplied label excerpts.
Certain dietary supplements with statins may increase the risk of adverse effects, including myopathy and rhabdomyolysis.
While the label discusses increased myopathy/rhabdomyolysis risk with certain drug classes (e.g., fibric acid derivatives, cyclosporine, strong CYP3A4 inhibitors), the provided excerpts do not support a general claim about dietary supplements increasing this risk.
Supplements like vitamin E, ginkgo biloba, or garlic may increase the risk of bleeding when taken with Lipitor.
No vitamin E, ginkgo, or garlic supplement interaction or bleeding-risk statement is provided in the supplied label excerpts.
Supplements like vitamin A or E can exacerbate liver damage when taken with Lipitor.
No vitamin A or vitamin E supplement interaction or liver-damage exacerbation statement is provided in the supplied label excerpts.
Supplements like creatine or HMB may increase the risk of muscle damage when taken with Lipitor.
No creatine or HMB supplement interaction or muscle-damage statement is provided in the supplied label excerpts.
Omega-3 fatty acids or plant sterols may be believed to complement Lipitor's effects and further lower cholesterol levels.
The provided label excerpts do not mention omega-3 fatty acids or plant sterols as complementary to atorvastatin or as further lowering cholesterol.
CoQ10 or vitamin D may be taken to mitigate potential side effects of Lipitor, such as muscle pain or fatigue.
The provided label excerpts do not support using CoQ10 or vitamin D to mitigate atorvastatin side effects.
Contradictions
Important Omissions
Boxed warning status (if any in the full label) and/or core labeled warnings should be addressed in interaction/safety claims (e.g., skeletal muscle and liver function testing guidance) rather than attributing bleeding/liver/muscle risks to unlisted supplements.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Several claims introduce specific supplement-related bleeding/liver/muscle risk and a mitigation strategy (CoQ10/vitamin D) that are not supported by the provided labeling excerpts. Unsupported interaction/mitigation statements could mislead patient behavior relative to labeled cautions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Needs Revision
Primary Issue
Multiple supplement-specific interaction and risk-mitigation assertions are not supported by the provided FDA label excerpts.
Suggested Improvement
Remove or rephrase any supplement-related bleeding/liver/muscle claims unless explicitly supported in the provided label text; keep only interactions explicitly stated (e.g., grapefruit juice increases atorvastatin concentrations) and any statin-related risks that are explicitly described (e.g., skeletal muscle events with certain concomitant drugs/classes).